CellCentric
To add a bio or update company history, please click update information.
News from CellCentric
CellCentric
6 May 2026
CellCentric raises a £160m Series D led by Venrock Healthcare Capital Partners for oral drug designed to treat multiple myeloma and other cancers
CellCentric develops inobrodib, an oral drug designed to treat multiple myeloma and other cancers. The treatment is intended to provide a new option for patients, including those who have already undergone multiple lines of therapy.
CellCentric
19 May 2025
CellCentric raises £90m Series C led by RA Capital and Forbion to advance first-in-class cancer drug
CellCentric is developing an oral cancer drug for multiple myeloma that targets a novel biological pathway, with ongoing clinical studies evaluating its use alone and in combination with existing therapies.
CellCentric
- Life Sciences
- Cambridge, United Kingdom
- £250m
- cellcentric.com
- Update Information
More venture news
- 18 Sept 2026
Big Picture BioBig Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences - 16 Sept 2026
Eterna RegenerativesEterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences - 15 Sept 2026
Magnitude BiosciencesMagnitude Biosciences raises £1.3m led by Northstar Ventures to run drug discovery screens in living nematode worms
EquityLife Sciences
